Prophylactic and therapeutic efficacy of an attenuated Listeria monocytogenes-based vaccine delivering HPV16 E7 in a mouse model

International Journal of Molecular Medicine

Volumn 30, Issue 6, 2012, Pages 1335-1342

  Jia, Yanyan ^a   Yin, Yuelan ^a   Duan, Feifei ^a   Fu, Hong ^a   Hu, Maozhi ^a   Gao, Yunfei ^a   Pan, Zhiming ^a   Jiao, Xinan ^a  

^a YANGZHOU UNIVERSITY   (China)

Author keywords

Antitumor immunity; Attenuated Listeria monocytogenes; Cervical cancer; Human papillomavirus type 16 E7

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; PROTEIN E7;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL GENOME; CANCER INHIBITION; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HISTOPATHOLOGY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; LISTERIA MONOCYTOGENES; LIVER; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; UTERINE CERVIX CANCER;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENETIC VECTORS; HUMAN PAPILLOMAVIRUS 16; IMMUNITY, CELLULAR; LISTERIA MONOCYTOGENES; LIVER; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; SPLEEN; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS; VACCINES, ATTENUATED;

EID: 84869396588     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1136     Document Type: Article

References (40)

1. Cohen J: Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 308: 618-621, 2005.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
3. Gatta G, Lasota MB and Verdecchia A: Survival of European women with gynaecological tumours, during the period 1978-1989. EUROCARE Working Group. Eur J Cancer 34: 2218-2225, 1998. (Pubitemid 29036889)
4. Schäfer A, Friedmann W, Mielke M, Schwartländer B and Koch MA: The increased frequency of cervical dysplasianeoplasia in women infected with the human immunodeficiency virus is related to the degree of immunosuppression. Am J Obstet Gynecol 164: 593-599, 1991.
5. Haupt RM and Sattler C: HPV vaccine continues to be safe and effective, and its benefits continue to outweigh its risks. Expert Rev Vaccines 9: 697-701, 2010.
6. Wu TC: Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. Eur J Immunol 37: 310-314, 2007.
7. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
8. Hung CF, Wu TC, Monie A and Roden R: Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev 222: 43-69, 2008. (Pubitemid 351430384)
9. Shahabi V, Seavey MM, Maciag PC, Rivera S and Wallecha A: Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther 18: 53-62, 2011.
10. Tangney M and Gahan CG: Listeria monocytogenes as a vector for anti-cancer therapies. Curr Gene Ther 10: 46-55, 2010.
11. Bruhn KW, Craft N and Miller JF: Listeria as a vaccine vector. Microbes Infect 9: 1226-1235, 2007. (Pubitemid 47375150)
12. Zenewicz LA and Shen H: Innate and adaptive immune responses to Listeria monocytogenes: a short overview. Microbes Infect 9: 1208-1215, 2007. (Pubitemid 47375148)
13. Darji A, Mohamed W, Domann E and Chakraborty T: Induction of immune responses by attenuated isogenic mutant strains of Listeria monocytogenes. Vaccine 21 (Suppl 2): 102-109, 2003.
14. Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M and Paterson Y: Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother 60: 931-942, 2011.
15. Wallecha A, Maciag PC, Rivera S, Paterson Y and Shahabi V: Construction and characterization of an attenuated Listeria monocytogenes strain for clinical use in cancer immunotherapy. Clin Vaccine Immunol 16: 96-103, 2009.
16. Seavey MM, Pan ZK, Maciag PC, et al: A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 15: 924-932, 2009.
17. Maciag PC, Radulovic S and Rothman J: The first clinical use of a live-attenuated Listeria monocytogenes vaccine: A Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27: 3975-3983, 2009.
18. Sewell DA, Pan ZK and Paterson Y: Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine 26: 5315-5320, 2008.
19. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC and Paterson Y: Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 167: 6471-6479, 2001. (Pubitemid 33081581)
20. Wallecha A, French C, Petit R, Singh R, Amin A and Rothman J: Lm-LLO-based immunotherapies and HPV-associated disease. J Oncol 2012: 542851, 2012.
21. Verch T, Pan ZK and Paterson Y: Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun 72: 6418-6425, 2004. (Pubitemid 39425422)
22. Cossart P and Toledo-Arana A: Listeria monocytogenes, a unique model in infection biology: an overview. Microbes Infect 10: 1041-1050, 2008.
23. Pamer EG: Immune responses to Listeria monocytogenes. Nat Rev Immunol 4: 812-823, 2004.
24. Schlüter D, Domann E, Buck C, et al: Phosphatidylcholine-specific phospholipase C from Listeria monocytogenes is an important virulence factor in murine cerebral listeriosis. Infect Immun 66: 5930-5938, 1998. (Pubitemid 28531855)
25. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF and Hohmann EL: Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun 70: 3592-3601, 2002. (Pubitemid 34665997)
26. Brockstedt DG and Dubensky TW: Promises and challenges for the development of Listeria monocytogenes-based immunotherapies. Expert Rev Vaccines 7: 1069-1084, 2008.
27. Monk IR, Gahan CG and Hill C: Tools for functional postgenomic analysis of Listeria monocytogenes. Appl Environ Microbiol 74: 3921-3934, 2008. (Pubitemid 351962416)
28. Yin Y, Tian D, Jiao H, et al: Pathogenicity and immunogenicity of a mutant strain of Listeria monocytogenes in the chicken infection model. Clin Vaccine Immunol 18: 500-505, 2011.
29. Jiao X, Lo-Man R, Winter N, Dériaud E, Gicquel B and Leclerc C: The shift of Th1 to Th2 immunodominance associated with the chronicity of Mycobacterium bovis bacille Calmette- Guérin infection does not affect the memory response. J Immunol 170: 1392-1398, 2003. (Pubitemid 36139506)
30. Berraondo P, Nouzé C, Préville X, Ladant D and Leclerc C: Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 67: 8847-8855, 2007. (Pubitemid 47437461)
31. Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ: Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res 46: 4109-4115, 1986. (Pubitemid 16075915)
32. Lin K, Doolan K, Hung CF and Wu TC: Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc 109: 4-24, 2010.
33. Yin YL, Zhang CJ, Tian DB, Pan ZM and Jiao XA: Kinetics of mutant Listeria monocytogenes strain yzuLM1-2 in murine infection model. Vet Sci in China 37: 850-853, 2007.
34. de Jong A, van der Hulst JM, Kenter GG, et al: Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. Int J Cancer 114: 274-282, 2005. (Pubitemid 40194297)
35. Vesely MD, Kershaw MH, Schreiber RD and Smyth MJ: Natural innate and adaptive immunity to cancer. Annu Rev Immunol 29: 235-271, 2011.
36. Yu YA, Shabahang S, Timiryasova TM, et al: Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 22: 313-320, 2004. (Pubitemid 38295764)
37. Gravekamp C and Paterson Y: Harnessing Listeria monocytogenes to target tumors. Cancer Biol Ther 9: 257-265, 2010.
38. Zeng Q, Peng S, Monie A, et al: Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther 22: 809-819, 2010.
39. Sharma RK, Schabowsky RH, Srivastava AK, et al: 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res 70: 3945-3954, 2010.
40. Ostrand-Rosenberg S: Animal models of tumor immunity, immunotherapy and cancer vaccines. Curr Opin Immunol 16: 143-150, 2004.